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Abstract
Brugada syndrome (BrS) is a condition defined by ST-segment alteration in right precordial leads and a risk of sudden death.
Because BrS is often associated with right bundle branch block and the TRPM4 gene is involved in conduction blocks, we
screened TRPM4 for anomalies in BrS cases. The DNA of 248 BrS cases with no SCN5A mutations were screened for TRPM4
mutations. Among this cohort, 20 patients had 11 TRPM4 mutations. Two mutations were previously associated with cardiac
conduction blocks and 9 were new mutations (5 absent from ,149000 control alleles and 4 statistically more prevalent in
this BrS cohort than in control alleles). In addition to Brugada, three patients had a bifascicular block and 2 had a complete
right bundle branch block. Functional and biochemical studies of 4 selected mutants revealed that these mutations resulted
in either a decreased expression (p.Pro779Arg and p.Lys914X) or an increased expression (p.Thr873Ile and p.Leu1075Pro) of
TRPM4 channel. TRPM4 mutations account for about 6% of BrS. Consequences of these mutations are diverse on channel
electrophysiological and cellular expression. Because of its effect on the resting membrane potential, reduction or increase
of TRPM4 channel function may both reduce the availability of sodium channel and thus lead to BrS.
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Introduction
Brugada syndrome (BrS) is characterized by ST-segment
elevation in the right precordial leads (V1– V3) of the electrocar-
diogram (ECG) with an associate risk of cardiac arrhythmia [1].
The mean age of BrS clinical appearance is around 40 years with a
strong male preponderance [2,3]. The ECG signature of BrS is
transient and can be unmasked by administration of sodium
channel blockers such as ajmaline or flecainide [2,4]. There are
internationally accepted criteria to establish a diagnosis of BrS [5].
The prevalence is estimated to be approximately 1/2500.
Although numerous environmental factors influence BrS clinical
and ECG expressivity, it is commonly accepted that it is a genetic
disease with usually an autosomal dominant pattern of inheritance
[6,7]. Since 1998, it has been established that about 15–25% of
BrS cases can be linked to mutations in SCN5A that encodes the
alpha subunit of cardiac sodium channel Nav1.5 [8]. Several other
genes have been implied in BrS such as GPD1L, CACNA1C,
CACNB2, SCN1B, KCNE3, SCN3B, KCNJ8 [9], CACNA2D1 [10],
KCND3 [11] and MOG1 [12] (for a review see [13]).
The transient receptor potential melastatin protein number 4
(TRPM4) is a calcium-activated nonselective cation channel,
member of a large family of transient receptor potential genes
[14]. TRPM4 has been recently implied in families with
progressive cardiac conduction blocks [15,16,17]. In this study,
we addressed the question whether BrS cases could be attributed
to TRPM4 mutations since BrS is frequently associated with
cardiac conduction anomalies. In a large cohort of 248 BrS cases
with no SCN5A mutation, 11 TRPM4 mutations were found in 20
unrelated individuals. The electrophysiological and cellular
expression consequences of 4 mutations were further studied.
These findings suggest that TRMP4 mutations accounts for about
6% of BrS.
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Materials and Methods
Ethics
A signed informed consent was obtained from all participants
(or the parents of minors) prior to history recording and blood
drawing. This study was specifically approved by the local ethics
committees (comite´ de protection des personnes Ouest IV and
Sud-Est II) and is in accordance with the last version of the
Declaration of Helsinki (The World Medical Association, 2002).
Clinical Evaluation
The diagnosis of Brugada is based on a type 1 ECG at rest prior
or after a drug challenge (ajmaline or flecainide). Medical history
was recorded and a clinical cardiologic examination was
performed on all patients. Most of the participants had additional
examinations including echocardiogram, stress test, ambulatory
ECG recording and electrophysiological study.
Genetic Analysis
DNA was extracted from blood samples according to standard
protocols. Mutation screening of TRPM4 (RefSeq NM_017636.3,
OMIM# 606936) was carried out by High Resolution Melting
(HRM) analysis (Rotor-Gene Q, Qiagen, Courtaboeuf, France)
followed by bi-directional sequencing of abnormal profiles or
directly by sequencing. The primers were already published [16].
The Exome Variant Server (http://evs.gs.washington.edu/EVS/
) was used to add controls to our series. Variants were confirmed
on a second sample and a second PCR product.
Preparation of TRPM4 Mutants
The complete human wild-type TRPM4 cDNA was cloned in
pcDNA4/TO vector (Invitrogen, Cergy Pontoise, France) [16].
Mutants were obtained by in vitro mutagenesis using QuickChange
II site-directed mutagenesis kit (Agilent Technologies, Massy,
France). Mutant cDNA clones were systematically resequenced
before use in further experiments.
Stable TRPM4 Mutant Expression
pcDNA4/TO plasmid containing the diverse TRPM4 mutants
were used to transfect T-RExTM 293 cell lines with Lipofectamine
2000 (Invitrogen, Cergy Pontoise, France) according to manufac-
turer specifications. The T-RExTM 293 cell line stably expresses
the tetracycline repressor protein enabling the silencing of the gene
of interest unless tetracycline is added to the culture medium. T-
RExTM 293 is a stable transformed cell line of HEK 293 obtained
with a plasmid that encodes the Tet repressor under the control of
the human CMV promoter. Several stable clones (3–4) of each
TRPM4 mutant were obtained according to Invitrogen protocol
by selecting with blasticidin (Tet repressor) and zeocin (TRPM4).
These stable clones were used for the electrophysiological study.
Electrophysiology
Currents were recorded from whole-cell or inside-out patches of
T-RexTM 293 transfected cells with a patch-clamp amplifier
Axopatch 200B (Axon instruments, Forster city, CA, USA) using
pClamp 9 software (Axon instruments). Experiments were
conducted at room temperature.
For patch-clamp experiments in inside-out conditions, cells were
bathed in a solution containing (in mM): 140 NaCl; 4.8 KCl; 1.2
MgCl2; 0.1 CaCl2; 10 glucose; and 10 HEPES, pH 7.4 (with
NaOH). Solutions perfused at the inside of the membrane
contained the previous solution (with 1 mM CaCl2) or, for
determination of ionic selectivity, a low NaCl solution (in mM):
42 NaCl; 1.2 MgCl2; 1 CaCl2; 10 glucose; and 10 HEPES,
supplemented with sucrose, pH 7.2.
In the whole-cell condition, TRPM4 currents were investigated
using a ramp protocol. The holding potential was 260 mV. The
400 ms increasing ramp from 2100 to +100 mV ends with a
20 ms step at +100 mV. The measured current was then reported
to cell size estimated by capacitance measurement. A new ramp
was performed every 5 s. As previously reported [18], in this
mode, the TRPM4 current develops with time after membrane
break to stabilize within 10 minutes. Biophysical properties were
then estimated after current stabilization. To investigate channels
activation time, a pulse protocol was used from a holding potential
at 0 mV to +80 mV during 100 ms.
For whole-cell recordings, pipette solutions contained (in mM)
156 CsCl, 1 MgCl2 and 10 HEPES (pH adjusted to 7.2 with
CsOH and [Ca2+] 1026 M). Bath and perfused solutions
contained (in mM) 156 NaCl, 5 CaCl2, 10 glucose and 10 HEPES
(pH adjusted to 7.4 with NaOH).
Biotinylation Assay
For biotinylation assay, HEK-293 cells were transiently
transfected with 240 ng of either HA-TRPM4 WT or mutants
cDNAs or the empty vector in a P100 dish (BD Falcon, Durham,
North Carolina, USA) mixed with 100 ul of OPTI-MEM I, 1 ul of
Plus reagent and 3 ul of Lipofectamine LTX (Invitrogen,
Carlsbad, California, USA). The cells were incubated for 48
hours at 37uC with 5% CO2. Following 48 hours of incubation,
HEK-293 cells transiently transfected with either HA-TRPM4
WT or mutant cDNAs or the empty vector were treated with EZ-
linkTM Sulfo-NHS-SS-Biotin (Thermo Scientific, Rockford, Illi-
nois, USA) 0.5 mg/ml in cold PBS for 15 minutes at 4uC.
Subsequently, the cells were washed twice with 200 mM Glycine
in cold PBS and twice with cold 1XPBS to inactivate and remove
the excess biotin, respectively. The cells were then lysed with 16
lysis buffer (50 mM HEPES pH 7.4; 150 mM NaCl; 1.5 mM
MgCl2; 1 mM EGTA pH 8; 10% Glycerol; 1% Triton X-100; 16
Complete Protease Inhibitor Cocktail (Roche, Mannheim, Ger-
many) for 1 hour at 4uC. Cell lysates were centrifuged at 16,000 g
4uC for 15 minutes. Two milligrams of the supernatant was
incubated with 50 ul Streptavidin Sepharose High Performance
beads (GE Healthcare, Uppsala, Sweden) for 2 hours at 4uC, and
the remaining supernatant was kept as the input. The beads were
subsequently washed five times with 16 lysis buffer before elution
with 50 ul of 26 NuPAGE sample buffer (Invitrogen, Carlsbad,
California, USA) plus 100 mM DTT at 37uC for 10 minutes.
These biotinylated fractions were analyzed as TRPM4 expressed
at the cell surface. The input fractions, analyzed as total expression
of TRPM4, were resuspended with 46NuPAGE Sample Buffer
plus 100 mM DTT to give a concentration of 1 mg/ml and
incubated at 37uC for 10 minutes.
Western Blotting
Both input and biotinylated fractions were analyzed on 8%
polyacrylamide gel and detected with anti-TRPM4 antibody
raised against the C terminal portion of TRPM4 from amino-acids
1138 to 1156 (Pineda, Berlin, Germany) and anti-a-actin A2066
(Sigma, St. Louis, Missouri, USA) antibodies. The blots obtained
were quantified using IGOR Pro (Wavemetrics, Lake Oswego,
Oregon, USA) software.
Statistics
Variant prevalence in the BrS vs control cohorts was tested by
the Fisher exact test and one sided p values are presented in table 1.
Mutant electrophysiological values and quantified bands on
TRPM4 Mutations in Brugada Syndrome
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Western blots were compared to wild type values using a Student t
test with a probability value below 0.05 considered as significant.
Results
Study Subjects and TRPM4 Screening
A cohort of 331 Brugada patients was studied. The diagnosis of
BrS was based on a spontaneous or drug-challenged type 1 ECG
pattern (figure 1A–B). All participants were screened for mutation
in the gene encoding the alpha subunit of the sodium channel gene
(SCN5A) and 83 patients (25%) had a SCN5A variant. These 83
patients were excluded for further study.
The screening of TRPM4 in this cohort of 248 BrS cases with
no SCN5A mutations evidenced 14 heterozygous variants in 25
unrelated individuals (figure 2 A–D). Five of these variants were
considered as mutations on the ground that they changed
conserved amino acids and were absent of our control series and
among European Americans and African Americans controls of
the Exome Variant Server (Table 1, Mutations). In addition, two
variants (p.A432T and p.G844D) were previously reported in
familial autosomal conduction block and their deleterious conse-
quences demonstrated by familial segregation and experimental
analysis [16]. Four variants were considered as putative genetic
BrS predisposing factors on the ground that they changed
conserved amino acids and they were found in the control
population but the prevalence in the BrS cohort was statistically
higher than in the control population (Table 1, Predisposing
factors). Finally, 3 variants were considered as polymorphisms on
the ground that they were found with a similar prevalence in the
BrS cohort and the control populations. All the mutations and
predisposing genetic factors were missense changes but we also
observed a single non-sense variation in the predisposing factor
sub-group (p.K914X). No patients had 2 mutations and/or
predisposing genetic factors.
Table 2 summarizes the clinical data of the 20 TRPM4 variant
carriers. There were many more males than females (18/2). The
average age at diagnosis was 49 years. The circumstances of
discovery were in 9 cases a routine ECG, in 1 case a chest pain, in
9 cases an episode of fainting and in a single case a sudden death.
Three had familial cases of sudden death and in one case the
father’s patient experienced palpitations. Twelve patients had a
spontaneous type 1 Brugada whereas 8 patients had a transition
from type 2 to type 1 induced by drug challenge (ajmaline in 4
cases and flecainide in 4 cases). Only 2 patients (patients 10 and
23) had QRS duration shorter than 100 msec. Ten patients had
an isolated incomplete RBBB whereas 3 had a isolated complete
RBBB. Three patients had a bifascicular block. Finally, a single
case (patient 13) had a prolonged QTc interval (458 ms).
Among the 5 new TRPM4 mutations, 3 were selected for further
electrophysiological and expression testing (P779R, T873I and
L1075P). In addition, 1 variant among the predisposing factor sub-
group, was also selected for further study: the mutation leading to
a stop codon (K914X). These 3 missense mutations gave a
Grantham score [19] of 89 or more. Grantham is a formula
estimating difference between amino acid according to their
physico-chemical properties. In addition, they were found in BrS
patients with no other TRPM4 variants (and no SCN5A variants), a
situation resulting in a simpler correlation between phenotype and
genotype.
Expression of TRPM4 Variants
TRPM4 current detection in the whole-cell
configuration. Wild type (WT) TRPM4 and all mutants
exhibited a characteristic outward rectifying current when
recorded in the whole-cell configuration (figure 3 A).
A significant decrease in current density was detected for
p.Pro779Arg and p.Lys914X transfected cells, in comparison to
WT transfected cells (figure 3 B). The p.Lys914X transfected cells
exhibited a current density similar to non-transfected HEK-293
cells, indicating that the mutant did not induce additional current.
Single channel conductance. In HEK-293 cells stably
expressing wild type TRPM4, a classical TRPM4 single current
was detected in the inside-out configuration (figure 4 A) with a
linear current-voltage relationship, providing a single channel
conductance of 21.160.6 pS (n= 9) in accordance with previous
reports [18,20]. Inside-out patches from p.Lys914X mutant
transfected cells did not exhibit any detectable current (n = 20)
(figure 4 B). Thus, this mutant was not further investigated. All
other mutants provided detectable currents with a current-voltage
relationship satisfactorily fitted to a linear regression (figure 4 B)
providing single channel conductances g similar to WT (figure 4
C).
On single channel traces provided for WT and each mutant in
figure 4, channel activity was higher at Vm= +40 mV than at
240 mV, indicating a channel sensitivity to voltage, a TRPM4
fingerprint.
Anion to cation permeability ratio. The anion to cation
permeability ratio was investigated in inside-out patches. Reducing
internal NaCl concentration from 145 mM to 42 mM shifted the
reversal potential (Vrev). A representative recording is provided for
p.Leu1075Pro (figure 5 A). The reversal potential of 2562 mV
(n= 4) for WT with 42 mM NaCl, corresponds to a permeability
ratio PNa/PCl of 14.2 according to the Goldman Hodgkin Katz
(GHK) equation. All mutants exhibited similar shifts in Vrev
indicating no variation in their permeability ratio (figure 5 B).
Sensitivity to calcium. Reducing internal calcium concen-
tration from 1023 to 1026 M suppressed 95.563.5% of WT
TRPM4 activity (figure 5 C). A similar rapid and reversible
decrease was observed for all mutants, (figure 5 D), indicating that
mutants conserve the TRPM4 sensitivity to calcium.
Sensitivity to voltage. The normalized open probability
(NPo) for each mutant was estimated during ramp protocols,
considering that the single channel conductance is linear in all
cases (see figure 4). NPo was estimated in function of voltage by
transforming the whole-cell current-voltage relationship (I/V) to
an NPo/V curve using the relation NPo= I/gV (figure 5 E). The
curve was then fitted to a Boltzman equation and voltage for half
maximal activation (V1/2) was determined (figure 5 F). V1/2 was
Figure 1. ECG of patient 9 with Brugada features. (A)
Unchallenged and (B) ajmaline-challenged ECG of patient 9 showing
a transition from Brugada type 2 to type 1. Note the characteristic ST
segment elevation in V1, V2 and V3.
doi:10.1371/journal.pone.0054131.g001
TRPM4 Mutations in Brugada Syndrome
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54131
significantly increased for p.Pro779Arg compared to WT, while
other mutants did not exhibited significant changes.
Activation time. Activation time of the current was deter-
mined using a pulse protocol from Vm =0 to +80 mV (figure S1
A). No significant differences were seen between mutants and WT
(figure S1 B).
Channel detection in the inside-out
configuration. Channel expression was evaluated in the
inside-out configuration by estimating the maximal number of
channels opened at Vm=+40 mV with 1023 M [Ca2+]i. As shown
in figure S2, it was observed a significant decrease in the number
of active channels for p.Pro779Arg compared to WT and as
mentioned before, no active channels were detected for
p.Lys914X. Other mutants did not shown significant variation
with WT.
Total and cell surface expression of TRPM4 mutant
channels. To test whether the BrS mutations altered the
cellular and cell surface expression level of TRPM4 channels,
WT and TRPM4 mutants were transiently transfected in HEK-
293 cells. Forty-eight hours post-transfection, the expression of
TRPM4 channels at the total protein level and at the cell surface
was assessed by quantitative Western blots (figure 6 and figure S3).
Under our migration conditions, two distinct bands representing
fully and core glycosylated forms of TRPM4 were observed. All
mutants showed a significantly altered expression of TRPM4. The
p.Pro779Arg and p.Lys914X mutants showed a decreased of total
expression whereas p.Lys914X was comparable to background
level. With an anti-HA antibody, a shorter band was visible in the
total and the surface expression demonstrating that p.Lys914X
results in the production of a truncated protein (figure S4). By
contrast, the p.Thr873Ile mutant showed a significant increase in
the core glycosylated form (lower band) of total and surface
expressions whereas the p.Leu1075Pro had a significant surface
expression increase.
Discussion
Here, we present a series of genetic variants found in a large
cohort of spontaneous or drug-challenged type 1 BrS patients.
Among the 14 TRPM4 variants, 3 were considered as polymor-
phisms. By contrast, the 11 remaining variants are presumably
pathogenic mutations. Among these 11 mutations, 5 are totally
absent from the very large control cohorts (more than 6 500
individuals), whereas 4 others have a statistically higher prevalence
in the BrS cohort than in the control cohorts. As an autosomal
condition with incomplete penetrance, it is not surprising that
genetic variants resulting in BrS or predisposing to BrS might be
found in large control cohorts. It is important to note that the size
of the BrS and control cohorts allow us to use statistical tests to
assess a difference of variant prevalence between both groups.
The variants p.A432T and p.G844D were previously found in
families with autosomal dominant cardiac conduction blocks [16].
None of the mutation carriers in the conduction block families had
(even retrospectively) an ECG suggestive of a BrS [16].
Interestingly, in this series of 20 BrS cases with TRPM4 mutations
or predisposing factors, 18 patients had a conduction block. The 2
patients with no widening of QRS had a rSr’ complex. This
observation suggests that TRPM4 mutation screening should be
considered in BrS when a widening of QRS or a rSr’ complex is
observed, a condition which not rare in BrS cases. Similar to the
families with cardiac conduction blocks, no cases of left bundle
branch block were observed.
Figure 2. Electrophoregrams of 3 missense mutations and localization of TRPM4 mutations (A–C). Electrophoregrams of 3 mutations. W
for A/T heterozygosity, and Y for C/T. (D): Localization of TRPM4 mutations resulting in conduction blocks (yellow), Brugada syndrome (blue) or both
(green).
doi:10.1371/journal.pone.0054131.g002
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The genetics of BrS is complex with incomplete penetrance and
phenocopies [7]. In addition, the causality link of the SCN5A
variants has been debated [7].It is possible that some BrS cases of
the present cohort carry mutations in one or several of the 10
other BrS susceptibility genes. The prevalence of mutations in
these 10 genes is low compared to the prevalence of SCN5A
mutation which accounts for a maximum of 30% [5]. The sum of
the prevalences of all the so far published gene mutations does
exceed 50% which suggests that about half of BrS cases have
mutation in up to now undiscovered genes. In conclusion, a
TRPM4 mutation was found in 9 of 331 BrS patient (2.7%), and a
mutation or a predisposing factor was found in 11 patients of the
same cohort (3.3%). This suggests that TRPM4 accounts for a
small percentage of BrS, and may thus explain that no mutations
were found in a much smaller series [17].
Among the 4 mutants that were further studied, the most
remarkable mutant is p.Lys914X since, as expected, it did not
produce any current. On Western blots, this mutant gave bands of
the same intensity as mock transfected HEK 293 cells consistent
with endogenous expression of TRPM4 in this cell line [20]
(Amarouch et al., in preparation). Nevertheless, using an anti-HA
antibody (the HA tag is located at the N terminus of transfected
Figure 3. Biophysical properties of WT and mutants TRPM4 channel in whole-cell configuration. (A): Representative current tracings
recorded in the whole cell conditions (ramp protocol under the traces) (B): Mean current density for WT and mutants estimated using the maximal
current recorded during the ending step of 20 ms at Vm = +100 mV (see A) and reported to cell capacitance. *p,0.05, **p,0.01, ***p,0.001,
****p,0.0001, n.s.: not significant. Numbers in bars = number of experiments. Error bar: standard error of the mean.
doi:10.1371/journal.pone.0054131.g003
Figure 4. Single channel currents. Inside-out single channel currents for WT and mutants TRPM4. Representative recordings at Vm = +40 and
240 mV and mean current/voltage relationship of WT (A) and mutants (B). No significant currents were detected for K914X mutant. (C): Single
channel conductance g of WT and mutants. Mean values for 5 to 9 experiments. ND: not determined.
doi:10.1371/journal.pone.0054131.g004
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TRPM4), we could detect a clear band corresponding to the
truncated protein in whole cell extract and in the plasma
membrane. Since the nonsense mutation is at the end of the
fourth trans-membrane domain, this protein lacks the 2 last trans-
membrane domains and the extra-cellular segment that forms the
pore region. Hence, it not surprising that no current could be
recorded. It should be stressed though that in our experimental
setting with stable transformed cell lines, we could not evaluate the
consequence of the combined expression of wild type and mutant
TRPM4 channels. Therefore, we cannot be certain that the
K914X variant is a dominant variant.
A decrease in current density was observed for the p.Pro779Arg
mutant. Pro779 is located in the second trans-membrane domain
and changes a hydrophobic residue to a non-hydrophobic residue.
The decrease in current density is probably due to a combination
of the decrease in channel expression evidenced by electrophys-
iological and biochemical assays, and by a modification of channel
voltage sensitivity leading to decreased current at physiological
voltages.
The variants p.Thr873Ile and p.Leu1075Pro showed no
alteration of whole-cell current, single channel properties, and
TRPM4 channel regulation. Western blots showed an increased
Figure 5. Na+/Cl2 permeability ratio and channels regulation. (A): PNa/PCl permeability ratio was estimated by changing the 145 mM NaCl
solution to a 42 mM NaCl solution to measure the shift of the current-voltage relationship. Voltage ramp protocol from Vm =2100 to +100 mV was
applied as showed for L1075P. (B): Reversal potential (Vrev) was estimated for WT and mutants as showed in A. PNa/PCl was calculated according to the
GHK equation. Similar results were obtained for mutants and WT. (C): Effect of [Ca2+]i on unitary channel activity was evaluated at Vm = +40 mV by
reducing [Ca2+]i from 10
23 M to 1026 M. A representative trace is provided for WT. Magnification allows observing single-channel currents. Label ‘‘c’’
indicates the current level corresponding to the closed state of all channels. (D): Mean % of inhibition of channel activity with [Ca2+]i = 10
26 M
compare to 1023 M for WT and mutants. No significant differences were detected. (E): Channel sensitivity to voltage was evaluated in the whole-cell
configuration by estimating NPo in function of voltage for each mutant during ramp protocols (see proceedings description in the text) as showed
for WT and P779R. (F): Mean voltage for half maximal activity (V1/2) estimated from traces as showed in E. P779R exhibited a significant increase in V1/
2. ** = significantly different from WT (p,0.01). Numbers in bars = number of experiments.
doi:10.1371/journal.pone.0054131.g005
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surface expression although the full glycosylated expression of
p.Thr873Ile did not reach a statistical threshold.
The mechanisms linking TRPM4 functional alterations and
ECG perturbations observed in BrS remain to be clarified. The
main perturbation characteristic of the pathology is the ST-
segment elevation observed in ECGs. Two models have been
proposed to account for the ST segment elevation in BrS: the
repolarizing disorder and the depolarizing disorder hypothesis
[21].
The repolarizing model is mainly based on the transmural
voltage gradient caused by heterogeneity in action potential (AP)
plateau among cells spanning the ventricular wall. Change in AP
dome depends on modifications of currents activated during the
early repolarization and plateau phases of the AP, mainly Ito, INa
Figure 6. Expression of TRPM4 channel in whole cell extracts and plasma membrane fraction. Several TRPM4 mutants show an alteration
of protein expression at a total level as well as at the cell surface. (A) Whole cell lysates from HEK-293 cells transfected with TRPM4 constructs used as
input, representing the total expression of TRPM4 protein. Quantification of the double bands, presumably fully and core glycosylated forms of
TRPM4, black and white arrrows, respectively, is shown on the bottom panels. (B) The biotinylated fractions from the same transfection represent the
amount of TRPM4 expressed at the cell surface. Quantification of the double bands is shown on the bottom panels. n = 3. *p,0.05, **p,0.01,
***p,0.001. Error bar: standard error of the mean.
doi:10.1371/journal.pone.0054131.g006
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and ICa. TRPM4 may participate in AP shape by promoting the
plateau. Due to its non-selective cationic selectivity, TRPM4
activation drives the membrane potential to 0 mV by conducting
an outward repolarizing K+ current at positive voltages, but an
inward depolarizing Na+ current at negative voltages. Because
TRPM4 is activated by internal Ca2+, it is more likely to activate
during the plateau phase when internal Ca2+ increased and thus
counteracts repolarizing K+ currents. Thereby, modifications of
TRPM4 expression by mutations would change AP dome. This
might explain the effect of mutants leading to increased expression
but not reduced expression since TRPM4 is only weakly expressed
in normal mammalian ventricle [15,16,22].
On the other hand, the depolarizing model depends more on
conduction delay in the right ventricular outflow tract (RVOT)
than differences in AP shape. RVOT perturbations are presented
as a substrate site for ventricular tachyarrhythmias [23,24]. While
TRPM4 is poorly expressed in mammalian ventricle, it is more
expressed in nodal tissue [15,16,25]. Interestingly, the embryologic
origin of RVOT is similar to those of atrioventricular regions [21]
but different from those of ventricles. According to this, TRPM4
might be abundantly expressed in RVOT. It can be speculated
that in analogy to the phenomenon of supernormal excitability
and conduction [26], both a gain-of-function and loss-of-function
of TRPM4 channels may lead to conduction slowing by reducing
the availability of Nav1.5 sodium channels. A gain-of-function
may depolarize the resting membrane potential and thus inactivate
sodium channels, while a loss-of-function could lead to a
hyperpolarization of the membrane potential, and so reduce
cellular excitability and conduction. These putative mechanisms of
action may be the basis of the observed phenotypic overlap found
in patients with SCN5A loss-of-function variants and TRPM4
variants.
In addition to direct effects of TRPM4 mutations cardiac
excitability, one has to consider that these mutants may also have
complex effects leading to BrS related to the fact that TRPM4 is
expressed in a variety of tissues [27]. Mutations may influence
neuro-hormonal regulation or cardiac development [28].
Altogether, this study suggests a role of TRPM4 in BrS
accounting for 2.7 to 6% of cases. In contrast to the first 4 TRPM4
mutations reported in patients with conduction blocks [15,16], the
electrophysiological consequences of the mutations resulting in
BrS is more diverse at least 2 mutations resulting in decreased
current density, 2 mutations with no electrophysiological anom-
alies in this experimental setting, and 2 previously reported
mutations with increased current. The complexity of the induced
disturbances in channel electrophysiology and trafficking is
increased by the genetic heterogeneity of BrS. In particular,
further studies are warranted to improve our understanding of the
interaction between channels that are permeable to sodium and
potassium.
Supporting Information
Figure S1 Activation time. Activation time of the current was
determined in the whole-cell configuration using a pulse protocol
from Vm =0 to +80 mV. Currents were fitted to a double
exponential to estimate time for half activation. A: Current trace
for WT under a pulse protocol as showed under the trace. B:
Mean time for half activation for WT and mutants. No significant
differences were seen between mutants and WT.
(TIF)
Figure S2 Number of channels per patch detected in
inside-out configuration. Mean number of TRPM4 channels
detected in each inside-out patch at Vm=+40 mV (pipette and
bath: 145 mM NaCl, 1023 M Ca2+). No detectable current was
observed for K914X. Number of experiments on top of bars.
(TIF)
Figure S3 Original western blot pictures that were
including more mutants than presented in figure 6.
Panels are from top to bottom: total expression and anti-TRPM4
antibody, total expression and anti-actin antibody; surface
expression and anti-TRPM4 antibody; surface expression and
anti-actin antibody. Lanes are from left-hand side to right-hand
side: empty plasmid, size marker, wild type TRPM4, and the
following TRPM4 mutants: L138P, R164W, A432T, G737R,
P779R, G844D, T873I, K914X, L941M, L1075P and E7K.
(TIF)
Figure S4 Original pictures of western blots showing
total and surface expression revealed with an anti-HA
antibody. These are the original Western blot pictures that
included the same lanes as in figure S3. The method used is
slightly different than in western blot of figure 6 and S3 in
particular an anti-HA antibody was used instead of an anti-
TRPM4 antibody. Note that a shorter band is clearly visible on the
L914X mutant line suggesting a truncated TRPM4 mutant
present in the total expression but also in the surface expression.
(TIF)
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